Koh Sze Kiat/E+ via Getty ImagesOn January 8, Ardelyx (NASDAQ:ARDX) provided a surprise business update. The stock surged that day to $8.18 (+33%) after management proclaimed that lead product IBSRELA (tenapanor for irritable bowel syndrome with constipation [IBS-C]) would corner 10% market share on its way to blockbuster status on US net product sales alone. Originally scheduled for February 29, the Q4 2023 financial report was bumped up to February 22, normally a good sign, but my previous coverage wa ...